{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:40:39Z","timestamp":1792197639041,"version":"4.4.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Soc Psychiatry Psychiatr Epidemiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Daridorexant, a novel dual orexin receptor antagonist, holds promise for managing insomnia. Although previous studies have identified a significant signal for suicidal ideation associated with daridorexant when compared with all other drugs, the significance when compared specifically with insomnia medications and the potential differences in reporting patterns of suicidal ideation across subgroups remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study utilized the data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Comparator-restricted disproportionality analyses were conducted using the reports with insomnia indication and commonly prescribed insomnia medications as comparators. Sensitivity analyses, stratified analyses, and subgroup comparative analyses were then performed to explore the potential differences in reporting patterns of suicidal ideation across subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The signal for suicidal ideation was no longer significant based on comparator-restricted disproportionality analyses. Sensitivity analyses revealed a reduction in the signal strength for suicidal ideation after excluding reports with depression-related co-reported adverse events, and depression was the only significant concurrent event that occurred simultaneously with suicidal ideation, suggesting that the co-reported depression may partly contribute to the reporting of suicidal ideation. Additionally, there may be potential differences in reporting patterns of daridorexant-associated suicidal ideation across subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although prior studies have identified a significant signal for suicidal ideation associated with daridorexant, the underlying relationship is likely multifactorial, with potential confounders such as underlying insomnia and co-reported depression. In addition, this study underscores the potential need for further verification of the differences in reporting daridorexant-associated suicidal ideation. The establishment of a definitive pharmacoepidemiological relationship between daridorexant and suicidal ideation warrants further research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00127-026-03227-9","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:02:19Z","timestamp":1792173739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Suicidal ideation associated with daridorexant treatment in insomnia patients: Comparator-restricted disproportionality analysis and assessment of potential heterogeneity in reporting patterns"],"prefix":"10.1007","author":[{"given":"Di","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"4","key":"3227_CR1","doi-asserted-by":"crossref","first-page":"e13604","DOI":"10.1111\/jsr.13604","volume":"31","author":"D Riemann","year":"2022","unstructured":"Riemann D, Benz F, Dressle RJ, Espie CA, Johann AF, Blanken TF et al (2022) Insomnia disorder: State of the science and challenges for the future. J Sleep Res 31(4):e13604","journal-title":"J Sleep Res"},{"issue":"1","key":"3227_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12875-024-02381-w","volume":"25","author":"H Selsick","year":"2024","unstructured":"Selsick H, Heidbreder A, Ellis J, Ferini-Strambi L, Garc\u00eda-Borreguero D, Leontiou C et al (2024) Assessment and management of chronic insomnia disorder: an algorithm for primary care physicians. BMC Prim Care 25(1):138","journal-title":"BMC Prim Care"},{"issue":"2","key":"3227_CR3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bcp.14180","volume":"86","author":"D Hoyer","year":"2020","unstructured":"Hoyer D, Allen A, Jacobson LH (2020) Hypnotics with novel modes of action. Brit J Clin Pharmaco 86(2):244\u2013249","journal-title":"Brit J Clin Pharmaco"},{"issue":"4 Suppl","key":"3227_CR4","first-page":"S85","volume":"26","author":"MT Liu","year":"2020","unstructured":"Liu MT (2020) Current and emerging therapies for insomnia. Am J Manag Care 26(4 Suppl):S85\u2013S90","journal-title":"Am J Manag Care"},{"key":"3227_CR5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","volume":"51","author":"TE Scammell","year":"2011","unstructured":"Scammell TE, Winrow CJ (2011) Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol 51:243\u2013266","journal-title":"Annu Rev Pharmacol"},{"issue":"10","key":"3227_CR6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11920-022-01357-w","volume":"24","author":"X Wu","year":"2022","unstructured":"Wu X, Xue T, Chen Z, Wang Z, Chen G (2022) Orexin Receptor Antagonists and Insomnia. Curr Psychiat Rep 24(10):509\u2013521","journal-title":"Curr Psychiat Rep"},{"issue":"2","key":"3227_CR7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0043-1770805","volume":"16","author":"D Sarathi Chakraborty","year":"2023","unstructured":"Sarathi Chakraborty D, Choudhury S, Lahiry S (2023) Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia. Sleep Sci 16(2):256\u2013264","journal-title":"Sleep Sci"},{"issue":"4","key":"3227_CR8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/1389200220666190206141814","volume":"20","author":"C Muehlan","year":"2019","unstructured":"Muehlan C, Fischer H, Zimmer D, Aissaoui H, Grimont J, Boss C et al (2019) Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer\/ Accelerator Mass Spectrometry. Curr Drug Metab 20(4):254\u2013265","journal-title":"Curr Drug Metab"},{"issue":"12","key":"3227_CR9","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/ijcp.12568","volume":"68","author":"L Citrome","year":"2014","unstructured":"Citrome L (2014) Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 68(12):1429\u20131441","journal-title":"Int J Clin Pract"},{"issue":"1","key":"3227_CR10","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L de Lecea","year":"1998","unstructured":"de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE et al (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. P Natl Acad Sci Usa 95(1):322\u2013327","journal-title":"P Natl Acad Sci Usa"},{"issue":"8","key":"3227_CR11","doi-asserted-by":"crossref","first-page":"e0136910","DOI":"10.1371\/journal.pone.0136910","volume":"10","author":"T Kishi","year":"2015","unstructured":"Kishi T, Matsunaga S, Iwata N (2015) Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. PLoS ONE 10(8):e0136910","journal-title":"PLoS ONE"},{"issue":"4","key":"3227_CR12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H et al (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92(4):573\u2013585","journal-title":"Cell"},{"issue":"10","key":"3227_CR13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40266-022-00977-4","volume":"39","author":"I Fietze","year":"2022","unstructured":"Fietze I, Bassetti CLA, Mayleben DW, Pain S, Seboek Kinter D, McCall WV (2022) Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial. Drug Aging 39(10):795\u2013810","journal-title":"Drug Aging"},{"issue":"5","key":"3227_CR14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/87551225221112546","volume":"38","author":"ES Onge","year":"2022","unstructured":"Onge ES, Phillips B, Rowe C (2022) Daridorexant: A New Dual Orexin Receptor Antagonist for Insomnia. J Pharm Technol 38(5):297\u2013303","journal-title":"J Pharm Technol"},{"issue":"2","key":"3227_CR15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/2589977515666221108093830","volume":"15","author":"DS Chakraborty","year":"2023","unstructured":"Chakraborty DS, Choudhury S, Lahiry S (2023) Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in the Treatment of Insomnia. Curr Drug Res Rev 15(2):149\u2013158","journal-title":"Curr Drug Res Rev"},{"issue":"11","key":"3227_CR16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40261-023-01310-6","volume":"43","author":"M Anliker-Ort","year":"2023","unstructured":"Anliker-Ort M, Dingemanse J, Janu L, Kaufmann P (2023) Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects. Clin Drug Invest 43(11):827\u2013837","journal-title":"Clin Drug Invest"},{"key":"3227_CR17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.sleep.2021.11.015","volume":"92","author":"M Boof","year":"2022","unstructured":"Boof M, Ufer M, Fietze I, Pepin J, Guern A, Lemoine V et al (2022) Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea. Sleep Med 92:4\u201311","journal-title":"Sleep Med"},{"issue":"12","key":"3227_CR18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/14740338.2023.2243217","volume":"22","author":"S Dutta","year":"2023","unstructured":"Dutta S, Singhal S, Shah R, Charan J, Dhingra S, Haque M (2023) Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis. Expert Opin Drug Saf 22(12):1237\u20131251","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"3227_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40268-024-00456-8","volume":"24","author":"I Zenklusen","year":"2024","unstructured":"Zenklusen I, Dingemanse J, Reh C, Gehin M, Kaufmann P (2024) Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects. Drugs R&D 24(1):97\u2013108","journal-title":"Drugs R&D"},{"issue":"7","key":"3227_CR20","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1007\/s10072-024-07326-w","volume":"45","author":"M Fernandes","year":"2024","unstructured":"Fernandes M, Placidi F, Mercuri NB, Liguori C (2024) Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study. Neurol Sci 45(7):3443\u20133448","journal-title":"Neurol Sci"},{"key":"3227_CR21","doi-asserted-by":"crossref","unstructured":"Magliocca M, Koopmans I, Vaillant C, Lemoine V, Zuiker R, Dingemanse J et al (2024) Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function. J Psychopharmacol :178624339","DOI":"10.1177\/02698811241293997"},{"key":"3227_CR22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.sleep.2024.07.036","volume":"122","author":"N Uchimura","year":"2024","unstructured":"Uchimura N, Ozone M, Suzuki M, Taniguchi M, Kuriyama K, Togo O et al (2024) Long-term safety and efficacy of daridorexant in Japanese patients with insomnia disorder. Sleep Med 122:64\u201370","journal-title":"Sleep Med"},{"issue":"9","key":"3227_CR23","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.3390\/jcm12093240","volume":"12","author":"SG Williams","year":"2023","unstructured":"Williams SG, Rodriguez-Cue D (2023) Use of Daridorexant among Patients with Chronic Insomnia: A Retrospective Observational Analysis. J Clin Med 12(9):3240","journal-title":"J Clin Med"},{"issue":"11","key":"3227_CR24","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00228-022-03381-4","volume":"78","author":"JBR Dos Santos","year":"2022","unstructured":"Dos Santos JBR, Da Silva MRR (2022) Daridorexant for the treatment of insomnia disorder: findings and implications. Eur J Clin Pharmacol 78(11):1749\u20131761","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3227_CR25","doi-asserted-by":"crossref","first-page":"23m14851","DOI":"10.4088\/JCP.23m14851","volume":"84","author":"L Citrome","year":"2023","unstructured":"Citrome L, Juday TR, Lundwall C (2023) Lemborexant and Daridorexant for the Treatment of Insomnia: An Indirect Comparison Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. J Clin Psychiat 84(6):23m14851","journal-title":"J Clin Psychiat"},{"issue":"3","key":"3227_CR26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/ph17030342","volume":"17","author":"G Cicala","year":"2024","unstructured":"Cicala G, Barbieri MA, Russo G, Salvo F, Spina E (2024) Safety of Dual Orexin Receptor Antagonist Daridorexant: A Disproportionality Analysis of Publicly Available FAERS Data. Pharmaceuticals-Base 17(3):342","journal-title":"Pharmaceuticals-Base"},{"key":"3227_CR27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jad.2024.07.034","volume":"362","author":"Q Wang","year":"2024","unstructured":"Wang Q, Zhou Q, Du Z, Lu R, Jiang Y, Zhu H (2024) Clinical safety of daridorexant in insomnia treatment: Analysis of FDA adverse event reports. J Affect Disorders 362:552\u2013559","journal-title":"J Affect Disorders"},{"key":"3227_CR28","doi-asserted-by":"crossref","first-page":"1436405","DOI":"10.3389\/fphar.2024.1436405","volume":"15","author":"M Jiang","year":"2024","unstructured":"Jiang M, Li H, Kong L (2024) Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database. Front Pharmacol 15:1436405","journal-title":"Front Pharmacol"},{"key":"3227_CR29","doi-asserted-by":"crossref","unstructured":"Sun Y, Xu T, Xu H (2025) Safety of dual orexin receptor antagonists: a real-world pharmacovigilance study. Expert Opin Drug Saf :1\u20137","DOI":"10.1080\/14740338.2025.2471520"},{"issue":"1","key":"3227_CR30","doi-asserted-by":"crossref","first-page":"22l14628","DOI":"10.4088\/JCP.22l14628","volume":"84","author":"B Nobile","year":"2022","unstructured":"Nobile B, Olie E, Courtet P (2022) Possible Suicidal Risk With Daridorexant, a New Treatment for Insomnia. J Clin Psychiat 84(1):22l14628","journal-title":"J Clin Psychiat"},{"issue":"4","key":"3227_CR31","doi-asserted-by":"crossref","first-page":"23lr14892","DOI":"10.4088\/JCP.23lr14892","volume":"84","author":"L Palagini","year":"2023","unstructured":"Palagini L, Geoffroy PA, Micoulaud-Franchi JA, Gemignani A, Riemann D (2023) Potential Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link. J Clin Psychiat 84(4):23lr14892","journal-title":"J Clin Psychiat"},{"issue":"4","key":"3227_CR32","doi-asserted-by":"crossref","first-page":"23lr14892a","DOI":"10.4088\/JCP.23lr14892a","volume":"84","author":"B Nobile","year":"2023","unstructured":"Nobile B, Courtet P (2023) Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia-Reply to Palagini et al. J Clin Psychiat 84(4):23lr14892a","journal-title":"J Clin Psychiat"},{"issue":"6","key":"3227_CR33","doi-asserted-by":"crossref","first-page":"e14196","DOI":"10.1111\/jsr.14196","volume":"33","author":"L Palagini","year":"2024","unstructured":"Palagini L, Alfi G, Gurrieri R, Annuzzi E, Caruso V, Gambini M et al (2024) Early experience with the new DORA daridorexant in patients with insomnia disorder and comorbid mental disturbances: Results of a naturalistic study with 3 months follow-up. J Sleep Res 33(6):e14196","journal-title":"J Sleep Res"},{"issue":"4","key":"3227_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00213-023-06320-y","volume":"240","author":"M Moline","year":"2023","unstructured":"Moline M, Asakura S, Beuckman C, Landry I, Setnik B, Ashworth J et al (2023) The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act. Psychopharmacology 240(4):699\u2013711","journal-title":"Psychopharmacology"},{"issue":"1","key":"3227_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s10194-024-01858-4","volume":"25","author":"JL Hu","year":"2024","unstructured":"Hu JL, Wu JY, Xu S, Qian SY, Jiang C, Zheng GQ (2024) Post-marketing safety concerns with rimegepant based on a pharmacovigilance study. J Headache Pain 25(1):169","journal-title":"J Headache Pain"},{"issue":"1","key":"3227_CR36","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1186\/s12885-024-13250-1","volume":"24","author":"J Qian","year":"2024","unstructured":"Qian J, Zhang S, Jiang C (2024) Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database. BMC Cancer 24(1):1486","journal-title":"BMC Cancer"},{"issue":"13","key":"3227_CR37","first-page":"1591710273","volume":"15","author":"C Jiang","year":"2024","unstructured":"Jiang C, Zheng X, Li P, Qian J, Li Q (2024) A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime. Ther Adv Drug Saf 15(13):1591710273","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"3227_CR38","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s40360-025-00960-w","volume":"26","author":"C Jiang","year":"2025","unstructured":"Jiang C, Qian J, Lu Y, Zheng J (2025) Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system. Bmc Pharmacol Toxico 26(1):129","journal-title":"Bmc Pharmacol Toxico"},{"issue":"4","key":"3227_CR39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/14740338.2024.2448205","volume":"24","author":"S Wu","year":"2025","unstructured":"Wu S, Qi Y, Jiang C, Zheng J (2025) Mining and analysis of adverse events associated with aducanumab: a real-world study using FDA Adverse Event Reporting System database. Expert Opin Drug Saf 24(4):469\u2013478","journal-title":"Expert Opin Drug Saf"},{"key":"3227_CR40","doi-asserted-by":"crossref","first-page":"1581606299","DOI":"10.1177\/20420986231154075","volume":"14","author":"AF Altebainawi","year":"2023","unstructured":"Altebainawi AF, Alfaraj LA, Alharbi AA, Alkhuraisi FF, Alshammari TM (2023) Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database. Ther Adv Drug Saf 14:1581606299","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"3227_CR41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000505376","volume":"43","author":"Y Song","year":"2020","unstructured":"Song Y, Xu YL, Lin Y, Zhao B, Sun Q (2020) Fractures due to aromatase inhibitor therapy for breast cancer: A real-world analysis of FAERS data in the past 15 years. Oncol Res Treat 43(3):96\u2013102","journal-title":"Oncol Res Treat"},{"issue":"1","key":"3227_CR42","doi-asserted-by":"crossref","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","volume":"12","author":"M Guo","year":"2022","unstructured":"Guo M, Shu Y, Chen G, Li J, Li F (2022) A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep-Uk 12(1):20601","journal-title":"Sci Rep-Uk"},{"issue":"1","key":"3227_CR43","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","volume":"12","author":"Y Yin","year":"2022","unstructured":"Yin Y, Shu Y, Zhu J, Li F, Li J (2022) A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib. Sci Rep-Uk 12(1):19555","journal-title":"Sci Rep-Uk"},{"key":"3227_CR44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.18433\/jpps33020","volume":"25","author":"Y Liu","year":"2022","unstructured":"Liu Y, Dong C, He X, Shu Y, Wu P, Zou J (2022) Post-marketing safety of vemurafenib: A real-world pharmacovigilance study of the FDA Adverse Event Reporting System. J Pharm Pharm Sci 25:377\u2013390","journal-title":"J Pharm Pharm Sci"},{"key":"3227_CR45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.euroneuro.2024.01.011","volume":"81","author":"M Fornaro","year":"2024","unstructured":"Fornaro M, Caiazza C, Rossano F, Cilmi F, De Prisco M, Vieta E et al (2024) Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials: NMA driving and hypnotics. Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacol 81:53\u201363","journal-title":"Eur Neuropsychopharmacology: J Eur Coll Neuropsychopharmacol"},{"issue":"6","key":"3227_CR46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V et al (2024) The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement. Drug Saf 47(6):575\u2013584","journal-title":"Drug Saf"},{"issue":"6","key":"3227_CR47","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V et al (2024) The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration. Drug Saf 47(6):585\u2013599","journal-title":"Drug Saf"},{"key":"3227_CR48","doi-asserted-by":"crossref","first-page":"115857","DOI":"10.1016\/j.psychres.2024.115857","volume":"335","author":"RD Gibbons","year":"2024","unstructured":"Gibbons RD, Hur K, Lavigne JE, Mann JJ (2024) Risk of suicide attempts and intentional self-harm on alprazolam. Psychiat Res 335:115857","journal-title":"Psychiat Res"},{"issue":"3","key":"3227_CR49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00004714-199606000-00003","volume":"16","author":"JM Jonas","year":"1996","unstructured":"Jonas JM, Hearron AEJ (1996) Alprazolam and suicidal ideation: a meta-analysis of controlled trials in the treatment of depression. J Clin Psychopharm 16(3):208\u2013211","journal-title":"J Clin Psychopharm"},{"key":"3227_CR50","doi-asserted-by":"crossref","first-page":"114777","DOI":"10.1016\/j.psychres.2022.114777","volume":"316","author":"H Khan","year":"2022","unstructured":"Khan H, Garg A, Yasmeen, Agarwal NB, Yadav DK, Ashif Khan M et al (2022) Zolpidem use and risk of suicide: A systematic review and meta-analysis. Psychiat Res 316:114777","journal-title":"Psychiat Res"},{"issue":"3","key":"3227_CR51","doi-asserted-by":"crossref","first-page":"zsz235","DOI":"10.1093\/sleep\/zsz235","volume":"43","author":"H Kim","year":"2020","unstructured":"Kim H, Kim Y, Myung W, Fava M, Mischoulon D, Lee U et al (2020) Risks of suicide attempts after prescription of zolpidem in people with depression: a nationwide population study in South Korea. Sleep 43(3):zsz235","journal-title":"Sleep"},{"key":"3227_CR52","doi-asserted-by":"crossref","first-page":"115576","DOI":"10.1016\/j.psychres.2023.115576","volume":"330","author":"WV McCall","year":"2023","unstructured":"McCall WV, Mercado K, Dzurny TN, McCloud LL, Krystal AD, Benca RM et al (2023) The effect of zolpidem-CR on the suicide item of the Hamilton Rating Scale for Depression in outpatients with depression, insomnia and suicidal ideation: Lessons learned. Psychiat Res 330:115576","journal-title":"Psychiat Res"},{"issue":"1","key":"3227_CR53","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1017\/S1092852925000318","volume":"30","author":"K Valentino","year":"2025","unstructured":"Valentino K, Teopiz K, Wong S, Le GH, Badulescu S, Johnson D et al (2025) A systematic review of anti-suicidal effects of sedative-hypnotics and cognitive behavioral therapy for insomnia. CNS Spectr 30(1):e45","journal-title":"CNS Spectr"},{"key":"3227_CR54","unstructured":"U.S. Food and Drug Administration. XANAX (alprazolam) tablets, for oral use [EB\/OL]. (2023) -1"},{"key":"3227_CR55","unstructured":"U.S. Food and Drug Administration. QUVIVIQ (daridorexant) tablets, for oral use [EB\/OL]. (2024) -9"},{"key":"3227_CR56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpsychires.2014.08.008","volume":"59","author":"P Feng","year":"2014","unstructured":"Feng P, Hu Y, Vurbic D, Akladious A, Strohl KP (2014) Chromosome 1 replacement increases brain orexins and antidepressive measures without increasing locomotor activity. J Psychiatr Res 59:140\u2013147","journal-title":"J Psychiatr Res"},{"issue":"1\u20133","key":"3227_CR57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jad.2006.10.019","volume":"100","author":"L Brundin","year":"2007","unstructured":"Brundin L, Petersen A, Bjorkqvist M, Traskman-Bendz L (2007) Orexin and psychiatric symptoms in suicide attempters. J Affect Disorders 100(1\u20133):259\u2013263","journal-title":"J Affect Disorders"},{"key":"3227_CR58","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fpsyt.2020.00097","volume":"11","author":"A Alacreu-Crespo","year":"2020","unstructured":"Alacreu-Crespo A, Olie E, Guillaume S, Girod C, Cazals A, Chaudieu I et al (2020) Dexamethasone Suppression Test May Predict More Severe\/Violent Suicidal Behavior. Front Psychiatry 11:97","journal-title":"Front Psychiatry"},{"issue":"1","key":"3227_CR59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40360-025-00858-7","volume":"26","author":"W Xie","year":"2025","unstructured":"Xie W, Xiang D, Li Y, Ge M, Deng A (2025) An exploratory study evaluating the 20 medications most commonly associated with suicidal ideation and self-injurious behavior in the FAERS database. Bmc Pharmacol Toxico 26(1):24","journal-title":"Bmc Pharmacol Toxico"},{"issue":"6","key":"3227_CR60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40261-023-01272-9","volume":"43","author":"EE Leppien","year":"2023","unstructured":"Leppien EE, Doughty BJ, Hurd KL, Strong KN, Piper BJ, McCall KL (2023) Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Clin Drug Invest 43(6):393\u2013399","journal-title":"Clin Drug Invest"},{"issue":"1","key":"3227_CR61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40360-023-00664-z","volume":"24","author":"D Dubrall","year":"2023","unstructured":"Dubrall D, Fekete S, Leitzen S, Paschke LM, Romanos M, Schmid M et al (2023) Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases. Bmc Pharmacol Toxico 24(1):22","journal-title":"Bmc Pharmacol Toxico"},{"key":"3227_CR62","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","volume":"82","author":"A Guirguis","year":"2024","unstructured":"Guirguis A, Chiappini S, Papanti PG, Vickers-Smith R, Harris D, Corkery JM et al (2024) Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. Eur Neuropsychopharm 82:82\u201391","journal-title":"Eur Neuropsychopharm"},{"issue":"1","key":"3227_CR63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","volume":"22","author":"J Zhou","year":"2024","unstructured":"Zhou J, Zheng Y, Xu B, Long S, Zhu LE, Liu Y et al (2024) Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. Bmc Med 22(1):65","journal-title":"Bmc Med"},{"issue":"1","key":"3227_CR64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","volume":"23","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, Kwan A (2024) The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf 23(1):47\u201355","journal-title":"Expert Opin Drug Saf"},{"key":"3227_CR65","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Mansur RB, Rosenblat JD, Teopiz KM, Kwan A (2024) The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf :1\u20136","DOI":"10.1080\/14740338.2024.2361300"},{"issue":"9","key":"3227_CR66","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/bcp.15802","volume":"89","author":"CA Gravel","year":"2023","unstructured":"Gravel CA, Douros A (2023) Considerations on the use of different comparators in pharmacovigilance: A methodological review. Brit J Clin Pharmaco 89(9):2671\u20132676","journal-title":"Brit J Clin Pharmaco"},{"issue":"1","key":"3227_CR67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4314\/ahs.v24i1.25","volume":"24","author":"HT Ali","year":"2024","unstructured":"Ali HT, Soliman ZA, Aborigiba F, Caprara ALF, Rissardo JP (2024) Trazodone-induced parkinsonism in a middle-aged male: A case report. Afr Health Sci 24(1):206\u2013212","journal-title":"Afr Health Sci"},{"key":"3227_CR68","doi-asserted-by":"crossref","unstructured":"McIntyre RS, Wong S, Kwan ATH, Rhee TG, Teopiz KM, Ho R et al (2024) Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf :1\u20135","DOI":"10.1080\/14740338.2024.2361300"},{"key":"3227_CR69","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.sleep.2023.11.033","volume":"113","author":"M Fornaro","year":"2024","unstructured":"Fornaro M, Caiazza C, De Simone G, Rossano F, de Bartolomeis A (2024) Insomnia and related mental health conditions: Essential neurobiological underpinnings towards reduced polypharmacy utilization rates. Sleep Med 113:198\u2013214","journal-title":"Sleep Med"},{"issue":"2","key":"3227_CR70","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","volume":"21","author":"E Mignot","year":"2022","unstructured":"Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA et al (2022) Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol 21(2):125\u2013139","journal-title":"Lancet Neurol"},{"issue":"4","key":"3227_CR71","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1097\/MJT.0000000000001647","volume":"30","author":"J Najib","year":"2023","unstructured":"Najib J, Toderika Y, Dima L (2023) Daridorexant, an Orexin Receptor Antagonist for the Management of Insomnia. Am J Ther 30(4):e360\u2013e368","journal-title":"Am J Ther"},{"issue":"6","key":"3227_CR72","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.5664\/jcsm.7172","volume":"14","author":"D Patel","year":"2018","unstructured":"Patel D, Steinberg J, Patel P (2018) Insomnia in the Elderly: A Review. J Clin Sleep Med 14(6):1017\u20131024","journal-title":"J Clin Sleep Med"},{"issue":"9","key":"3227_CR73","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/10600280221143794","volume":"57","author":"J Park","year":"2023","unstructured":"Park J, Render PharmD KP, Cates PharmD DW (2023) Daridorexant: Comprehensive Review of A New Oral Agent for the Treatment of Insomnia. Ann Pharmacother 57(9):1076\u20131087","journal-title":"Ann Pharmacother"},{"issue":"4 Suppl","key":"3227_CR74","first-page":"S76","volume":"26","author":"JA Dopheide","year":"2020","unstructured":"Dopheide JA (2020) Insomnia overview: epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy. Am J Manag Care 26(4 Suppl):S76\u2013S84","journal-title":"Am J Manag Care"},{"issue":"3","key":"3227_CR75","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cger.2021.04.002","volume":"37","author":"MR Ebben","year":"2021","unstructured":"Ebben MR (2021) Insomnia: Behavioral Treatment in the Elderly. Clin Geriatr Med 37(3):387\u2013399","journal-title":"Clin Geriatr Med"},{"key":"3227_CR76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jad.2015.02.010","volume":"177","author":"C Cooper","year":"2015","unstructured":"Cooper C, Rantell K, Blanchard M, McManus S, Dennis M, Brugha T et al (2015) Why are suicidal thoughts less prevalent in older age groups? Age differences in the correlates of suicidal thoughts in the English Adult Psychiatric Morbidity Survey 2007. J Affect Disorders 177:42\u201348","journal-title":"J Affect Disorders"},{"issue":"2","key":"3227_CR77","first-page":"115","volume":"18","author":"WF Chen","year":"1995","unstructured":"Chen WF, Huang SC (1995) Pollakiuria: extraordinary daytime urinary frequency a common problem in pediatric practice. Changgeng Yi Xue Za Zhi 18(2):115\u2013119","journal-title":"Changgeng Yi Xue Za Zhi"},{"issue":"2","key":"3227_CR78","first-page":"93","volume":"50","author":"J Krieger","year":"1993","unstructured":"Krieger J, Petiau C, Sforza E, Delanoe C, Hecht MT, Chamouard V (1993) Nocturnal pollakiuria is a symptom of obstructive sleep apnea. Urol Int 50(2):93\u201397","journal-title":"Urol Int"},{"key":"3227_CR79","doi-asserted-by":"crossref","first-page":"bcr2017222037","DOI":"10.1136\/bcr-2017-222037","volume":"2017","author":"J Petrous","year":"2017","unstructured":"Petrous J, Furmaga K (2017) Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts. Bmj Case Rep 2017:bcr2017222037","journal-title":"Bmj Case Rep"},{"key":"3227_CR80","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.2147\/DDDT.S73224","volume":"9","author":"EL Sutton","year":"2015","unstructured":"Sutton EL (2015) Profile of suvorexant in the management of insomnia. Drug Des Devel Ther 9:6035\u20136042","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"3227_CR81","first-page":"612","volume":"16","author":"Q Wang","year":"2024","unstructured":"Wang Q, Zhao Y, Qin X, Tian J (2024) Deciphering relationship between depression and microbial molecules based on multi-omics: A case study of Chaigui Granules. Chin Herb Med 16(4):612\u2013621","journal-title":"Chin Herb Med"},{"issue":"1","key":"3227_CR82","first-page":"132","volume":"16","author":"W Zhao","year":"2024","unstructured":"Zhao W, Ji C, Zheng J, Zhou S, Tian J, Han Y et al (2024) Effects of Xiaoyao San on exercise capacity and liver mitochondrial metabolomics in rat depression model. Chin Herb Med 16(1):132\u2013142","journal-title":"Chin Herb Med"},{"issue":"4","key":"3227_CR83","first-page":"798","volume":"17","author":"J He","year":"2025","unstructured":"He J, Zhao Z, Ye Y, Zhai Y, Yu D, Gao F et al (2025) Microbiota basis of antidepressant effects of Zhi-zi-chi Decoction: Lactobacillus rhamnosus and gut microbiota metabolism. Chin Herb Med 17(4):798\u2013807","journal-title":"Chin Herb Med"},{"issue":"4","key":"3227_CR84","first-page":"790","volume":"17","author":"M Huang","year":"2025","unstructured":"Huang M, He Y, Yang T, Yu L, Lei Q, Gao L et al (2025) Jiaotaiwan activates serum SCFAs and upregulates cAMP-PKA-CREB-BDNF signaling pathway for antidepressant effects: A multicenter, randomized, controlled study. Chin Herb Med 17(4):790\u2013797","journal-title":"Chin Herb Med"},{"issue":"3","key":"3227_CR85","first-page":"358","volume":"16","author":"X Du","year":"2024","unstructured":"Du X, Zhang M, Wang S, Li J, Zhang J, Liu D (2024) Ethnopharmacology, chemical composition and functions of Cymbopogon citratus. Chin Herb Med 16(3):358\u2013374","journal-title":"Chin Herb Med"},{"key":"3227_CR86","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jclinepi.2023.08.010","volume":"162","author":"L Gaucher","year":"2023","unstructured":"Gaucher L, Sabatier P, Katsahian S, Jannot AS (2023) Pharmacovigilance studies without a priori hypothesis: systematic review highlights inappropriate multiple testing correction procedures. J Clin Epidemiol 162:127\u2013134","journal-title":"J Clin Epidemiol"}],"container-title":["Social Psychiatry and Psychiatric Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00127-026-03227-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00127-026-03227-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00127-026-03227-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:56:34Z","timestamp":1792194994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00127-026-03227-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":86,"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1007\/s00127-026-03227-9","relation":{},"ISSN":["0933-7954","1433-9285"],"issn-type":[{"value":"0933-7954","type":"print"},{"value":"1433-9285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Ethical approval was not required for this study because we used the FAERS database, which is a free open-access database.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}